Juno Therapeutics' P2P Acquisition

Juno Therapeutics raised a round of funding on March 06, 2018. Investors include Celgene.

Juno Therapeutics (NASDAQ: JUNO) is a clinical-stage company that brings together three of the world's leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cance…

Articles about Juno Therapeutics' P2P Acquisition: